ACTU

Actuate Therapeutics, Inc. Common stock

2.31

USD

ACTU Earnings Reports

Positive Surprise Ratio

ACTU beat 2 of 4 last estimates.

50%

Next Report

Date of Next Report

May 15, 2026

Estimate for Q1 26 (Revenue/ EPS)

-$0.25

Implied change from Q4 25 (Revenue/ EPS)

Implied change from Q1 25 (Revenue/ EPS)

-21.88%

Actuate Therapeutics, Inc. Common stock earnings per share and revenue

On Mar 13, 2026, ACTU reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.24 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.

Looking ahead to Q1 26, -- analysts forecast an EPS of -0.25 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

FAQ

What were Actuate Therapeutics, Inc. Common stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Actuate Therapeutics, Inc. Common stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.

How did the market react to Actuate Therapeutics, Inc. Common stock's Q4 2025 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Actuate Therapeutics, Inc. Common stock expected to report next?

The next earning report is scheduled for May 15, 2026.

What are the forecasts for Actuate Therapeutics, Inc. Common stock's next earnings report?

Based on -- analysts, Actuate Therapeutics, Inc. Common stock is expected to report EPS of -$0.25 and revenue of -- for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.